Cartesian Therapeutics Inc.
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | -273.1% | – | – | – | – | |
| – | +20.8% | -23.2% | -6.5% | +30.0% | +107.9% | -63.8% | +70.6% | +2.8% | -34.5% | +36.5% | +157.1% | |
| – | -8.1% | +82.3% | +99.0% | +40.0% | -9.7% | +5.1% | +42.4% | +45.0% | +101.2% | -70.8% | +59.8% | |
| – | -12.5% | +103.4% | +114.6% | +10.5% | +6.5% | +165.3% | -34.5% | -180.2% | – | – | – | |
| – | – | +2,992.0% | -46.1% | -111.0% | – | – | -156.7% | – | – | -216.5% | – | |
| – | +412.3% | -49.6% | +25.1% | +20.6% | -94.7% | +1,634.0% | +33.1% | +10.7% | -82.8% | +4,314.1% | -40.0% | |
| – | +1,961.2% | +372.3% | -90.5% | – | -99.1% | -423.6% | +2,213.1% | -12.5% | – | -125.3% | -37.6% | |
| – | – | – | +457.4% | – | – | +557.1% | – | – | – | – | – | |
| – | +23,825.5% | +118.9% | -99.7% | +8.9% | -85.7% | +557.1% | -12.5% | +17.4% | -3,364.0% | -100.0% | – | |
| – | +154.3% | -29.8% | +0.0% | -134.9% | +0.0% | – | -100.0% | – | – | -100.0% | – | |
| – | +77.2% | +54.1% | -2.4% | -98.9% | +14,970.4% | -86.3% | +266.6% | -25.9% | -133.5% | – | -104.8% | |
| – | +96.4% | +54.4% | -53.8% | -378.3% | – | -8.1% | -150.8% | – | – | – | -164.3% | |
| – | – | – | – | – | – | – | -280.4% | – | – | – | – |
Data as of: September 22, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.